ATTAC-MCC: Phase I/II study of autologous CD8+ and CD4+ transgenic T cells expressing a high affinity MCPyV-specific TCR combined with checkpoint inhibitors and class I MHC-upregulation in patients with metastatic MCC refractory to PD-1 axis blockade.

MCC1 TCR - Fred Hutchinson Cancer Research Center, 2seventy bio, Affini-T Therap

https://meetings.asco.org/abstracts-presentations/213292

Joshua Veatch; Ananth Akkiraju; Agus Darwanto; Sean Garrity; Damien Hallet; Kim Nguyen; Piotr Pierog; Tomasz Sewastianik; Markus P Vallaster; Loic Vincent; Aude Chapuis

Apr 28, 2022